Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus

Jason Seewoodhary1, Leanne Griffin1, Stephen C Bain11Department of Diabetes and Endocrinology, Swansea School of Medicine, University of Wales, Swansea SA2 8PP, UKAbstract: Exenatide (also known as exendin-4) is a glucagon-like peptide-1 mimetic, which is indicated for the treatment of type 2 diabet...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jason Seewoodhary, Leanne Griffin, Stephen C Bain
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/859b87f723894cad807b0051bd2e8a75
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:859b87f723894cad807b0051bd2e8a75
record_format	dspace
spelling	oai:doaj.org-article:859b87f723894cad807b0051bd2e8a752021-12-02T00:47:43ZCritical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus1178-7007https://doaj.org/article/859b87f723894cad807b0051bd2e8a752010-05-01T00:00:00Zhttp://www.dovepress.com/critical-appraisal-of-once-weekly-formulation-of-exenatide-in-the-cont-a4451https://doaj.org/toc/1178-7007Jason Seewoodhary1, Leanne Griffin1, Stephen C Bain11Department of Diabetes and Endocrinology, Swansea School of Medicine, University of Wales, Swansea SA2 8PP, UKAbstract: Exenatide (also known as exendin-4) is a glucagon-like peptide-1 mimetic, which is indicated for the treatment of type 2 diabetes mellitus. The currently available formulation of this drug is a twice-daily exenatide (exenatide BID) injection that should be administered within 60 minutes of food. Once-weekly exenatide (exenatide QW) formulation is now being assessed in a clinical trial program. Exenatide QW has been shown to be the only noninsulin monotherapy to achieve glycosylated hemoglobin levels of &lt;7% in &gt;75% of treated patients. It has also demonstrated potential cardiovascular benefits by lowering total and low-density lipoprotein cholesterol concentrations, triglyceride levels, and both systolic and diastolic blood pressure. In addition, patients treated with exenatide QW achieved significant weight loss, which may also lead to significant cardiovascular risk reduction. Exenatide QW is associated with a lower incidence of gastrointestinal adverse effects compared with exenatide BID, and no patients treated with exenatide QW monotherapy experienced a confirmed hypoglycemic event. Exenatide QW results in 24-hour coverage with exenatide concentrations that are known to improve glycemic control and remain well tolerated in patients with type 2 diabetes mellitus. This review defines the state of play with exenatide QW by critically appraising its role in clinical practice.Keywords: GLP-1 mimetic, HbA1c, weight loss Jason SeewoodharyLeanne GriffinStephen C BainDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2010, Iss default, Pp 165-172 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Specialties of internal medicine RC581-951
spellingShingle	Specialties of internal medicine RC581-951 Jason Seewoodhary Leanne Griffin Stephen C Bain Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
description	Jason Seewoodhary1, Leanne Griffin1, Stephen C Bain11Department of Diabetes and Endocrinology, Swansea School of Medicine, University of Wales, Swansea SA2 8PP, UKAbstract: Exenatide (also known as exendin-4) is a glucagon-like peptide-1 mimetic, which is indicated for the treatment of type 2 diabetes mellitus. The currently available formulation of this drug is a twice-daily exenatide (exenatide BID) injection that should be administered within 60 minutes of food. Once-weekly exenatide (exenatide QW) formulation is now being assessed in a clinical trial program. Exenatide QW has been shown to be the only noninsulin monotherapy to achieve glycosylated hemoglobin levels of &lt;7% in &gt;75% of treated patients. It has also demonstrated potential cardiovascular benefits by lowering total and low-density lipoprotein cholesterol concentrations, triglyceride levels, and both systolic and diastolic blood pressure. In addition, patients treated with exenatide QW achieved significant weight loss, which may also lead to significant cardiovascular risk reduction. Exenatide QW is associated with a lower incidence of gastrointestinal adverse effects compared with exenatide BID, and no patients treated with exenatide QW monotherapy experienced a confirmed hypoglycemic event. Exenatide QW results in 24-hour coverage with exenatide concentrations that are known to improve glycemic control and remain well tolerated in patients with type 2 diabetes mellitus. This review defines the state of play with exenatide QW by critically appraising its role in clinical practice.Keywords: GLP-1 mimetic, HbA1c, weight loss
format	article
author	Jason Seewoodhary Leanne Griffin Stephen C Bain
author_facet	Jason Seewoodhary Leanne Griffin Stephen C Bain
author_sort	Jason Seewoodhary
title	Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
title_short	Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
title_full	Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
title_fullStr	Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
title_full_unstemmed	Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
title_sort	critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/859b87f723894cad807b0051bd2e8a75
work_keys_str_mv	AT jasonseewoodhary criticalappraisalofonceweeklyformulationofexenatideinthecontroloftype2diabetesmellitus AT leannegriffin criticalappraisalofonceweeklyformulationofexenatideinthecontroloftype2diabetesmellitus AT stephencbain criticalappraisalofonceweeklyformulationofexenatideinthecontroloftype2diabetesmellitus
_version_	1718403509761605632

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus

Ejemplares similares